PMV Pharmaceuticals reported net income of -$18.15M for the quarter ended Jun 2026. This income statement covers 28 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating items | ||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 9.16M | 12.17M | 11.84M | 11.46M | 13.67M | 15.03M | 15.07M | 13.84M | 13.59M | 13.38M | 13.19M | 14.63M | 16.95M | 13.77M | 17.44M | 18.40M | 18.21M | 15.83M | 15.33M | 14.68M | ||||||||
| Selling, General & AdministrativeSG&A | 5.93M | 6.30M | 6.78M | 6.42M | 5.71M | 6.14M | 6.41M | 6.28M | 6.04M | 5.52M | 5.04M | 5.54M | 4.94M | 11.40M | 4.12M | 4.48M | 4.31M | 3.42M | 3.69M | 4.21M | ||||||||
| Operating ExpensesOpex | 15.10M | 18.47M | 18.62M | 17.89M | 19.38M | 21.16M | 21.48M | 20.12M | 19.63M | 18.90M | 18.22M | 20.17M | 21.89M | 25.17M | 21.56M | 22.88M | 22.52M | 19.24M | 19.02M | 18.88M | ||||||||
| Operating IncomeOp. Inc | -15.10M | -18.47M | -18.62M | -17.89M | -19.38M | -21.16M | -21.48M | -20.12M | -19.63M | -18.90M | -18.22M | -20.17M | -21.89M | -25.17M | -21.56M | -22.88M | -22.52M | -19.24M | -19.02M | -18.88M | ||||||||
| EBIT | -15.10M | -18.47M | -18.62M | -17.89M | -19.38M | -21.16M | -21.48M | -20.12M | -19.63M | -18.90M | -18.22M | -20.17M | -21.89M | -25.17M | -21.56M | -22.88M | -22.52M | -19.24M | -19.02M | -18.88M | ||||||||
| Non-operating items | ||||||||||||||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.10M | 0.11M | 0.19M | 0.57M | 1.14M | 1.82M | 2.35M | 2.69M | 2.99M | 3.15M | 2.95M | 2.78M | 2.74M | 2.17M | 1.93M | 1.67M | 1.46M | 1.23M | 0.98M | 0.80M | ||||||||
| Net income details | ||||||||||||||||||||||||||||
| EBT | -14.99M | -18.36M | -18.43M | -17.31M | -18.24M | -19.34M | -19.13M | -17.43M | -16.64M | -15.76M | -15.27M | -17.39M | -19.15M | -23.10M | -19.63M | -21.20M | -21.07M | -18.03M | -18.04M | -18.08M | ||||||||
| Tax ProvisionsTaxes | 0.02M | 0.00M | -0.00M | -0.01M | 0.00M | -0.00M | -0.00M | -16.17M | 0.07M | -2.20M | 0.01M | -0.01M | -14.58M | 0.00M | ||||||||||||||
| Profit After TaxPAT | -15.01M | -18.44M | -18.43M | -17.31M | -18.23M | -18.77M | -19.13M | -17.44M | -16.67M | -15.76M | -15.27M | -1.21M | -19.23M | -23.09M | -17.44M | -21.27M | -21.06M | -18.04M | -18.04M | -18.15M | ||||||||
| Income from Continuing OperationsIncome (Continuing) | -15.01M | -18.36M | -18.43M | -17.31M | -18.23M | -19.34M | -19.13M | -17.44M | -16.64M | -15.76M | -15.27M | -1.21M | -19.23M | -23.10M | -17.44M | -21.21M | -21.06M | -3.45M | -18.04M | -18.09M | ||||||||
| Consolidated Net IncomeConsol Net Inc. | -15.01M | -18.36M | -18.43M | -17.31M | -18.23M | -19.34M | -19.13M | -17.44M | -16.64M | -15.76M | -15.27M | -1.21M | -19.23M | -23.10M | -17.44M | -21.21M | -21.06M | -3.45M | -18.04M | -18.09M | ||||||||
| Income towards Parent CompanyParent Net Inc | -15.01M | -18.36M | -18.43M | -17.31M | -18.23M | -19.34M | -19.13M | -17.44M | -16.64M | -15.76M | -15.27M | -1.21M | -19.23M | -23.10M | -17.44M | -21.21M | -21.06M | -3.45M | -18.04M | -18.09M | ||||||||
| Net Income towards Common StockholdersNet Income | -15.01M | -18.36M | -18.43M | -17.31M | -18.23M | -19.34M | -19.13M | -17.44M | -16.64M | -15.76M | -15.27M | -1.21M | -19.23M | -23.10M | -17.44M | -21.21M | -21.06M | -3.45M | -18.04M | -18.09M | ||||||||
| Additional items | ||||||||||||||||||||||||||||
| EPS (Basic) | -0.33 | -0.41 | -0.41 | -0.38 | -0.40 | -0.42 | -0.42 | -0.38 | -0.34 | -0.33 | -0.30 | -0.02 | -0.37 | -0.45 | -0.34 | -0.41 | -0.40 | -0.07 | -0.34 | -0.34 | ||||||||
| EPS (Diluted) | -0.33 | -0.41 | -0.41 | -0.38 | -0.40 | -0.42 | -0.42 | -0.38 | -0.34 | -0.33 | -0.30 | -0.02 | -0.37 | -0.45 | -0.34 | -0.41 | -0.40 | -0.07 | -0.34 | -0.34 | ||||||||
| Shares Outstanding | 45.30M | 45.14M | 45.47M | 45.57M | 45.62M | 45.59M | 45.77M | 45.81M | 49.05M | 48.01M | 51.45M | 51.48M | 51.57M | 51.58M | 51.95M | 52.01M | 52.99M | 52.54M | 53.33M | 53.39M | ||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 45.30M | 45.14M | 45.47M | 45.57M | 45.62M | 45.59M | 45.77M | 45.81M | 49.05M | 48.01M | 51.45M | 51.48M | 51.57M | 51.58M | 51.95M | 52.01M | 52.99M | 52.54M | 53.33M | 53.39M | ||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 45.35M | 45.43M | 45.53M | 45.62M | 45.62M | 45.77M | 45.77M | 46.14M | 51.16M | 51.45M | 51.45M | 51.52M | 51.75M | 51.94M | 51.95M | 52.99M | 52.99M | 53.33M | 53.33M | 53.46M | ||||||||
| EBITDA | -15.10M | -18.47M | -18.62M | -17.89M | -19.38M | -21.16M | -21.48M | -20.12M | -19.63M | -18.90M | -18.22M | -20.17M | -21.89M | -25.17M | -21.56M | -22.88M | -22.52M | -19.24M | -19.02M | -18.88M | ||||||||
| Tax Rate | -0.13% | -0.01% | 0.01% | 0.05% | -0.02% | 0.01% | 0.01% | 93.02% | -0.39% | 11.19% | -0.02% | 0.03% | 80.87% | -0.02% |